Efficacy of a Proprietary Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst®) in Women with Polycystic Ovary Syndrome (PCOS): a Randomized, Double-Blind, Placebo-Controlled Study.

IF 6.8 4区 医学 Q1 NUTRITION & DIETETICS
Amarjeet Singh, Shalini Gainder, Pradipta Banerjee, Apurva Goel, Pawan Kumar, Banashree Mondal, Samudra P Banik, Debasis Bagchi
{"title":"Efficacy of a Proprietary Fenugreek Seed Extract (<i>Trigonella foenum-graecum</i>, Furocyst®) in Women with Polycystic Ovary Syndrome (PCOS): a Randomized, Double-Blind, Placebo-Controlled Study.","authors":"Amarjeet Singh,&nbsp;Shalini Gainder,&nbsp;Pradipta Banerjee,&nbsp;Apurva Goel,&nbsp;Pawan Kumar,&nbsp;Banashree Mondal,&nbsp;Samudra P Banik,&nbsp;Debasis Bagchi","doi":"10.1080/27697061.2022.2126410","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenemia, a quite common heterogenous endocrine/hormonal disorder, and accompanied by elevated androgen level, menstrual irregularity, and hirsutism. The consequences include infertility or miscarriage. It is a challenging problem to the physicians. In a one-arm, non-randomized preliminary investigation in fifty premenopausal women, we demonstrated the efficacy of Furocyst<sup>®</sup>, a patented, standardized <i>Trigonella foenum-graecum</i> extract, in ameliorating the symptoms of PCOS over a period of 90 consecutive days.</p><p><strong>Objective: </strong>In the present study, a double-blind, two-arm, single-center, randomized, comparative study was conducted to assess the efficacy of Furocyst<sup>®</sup> (2 capsules of 500 mg/day) in 208 pre-menopausal women diagnosed with PCOS.</p><p><strong>Methods: </strong>Ethical committee approval was obtained. A total of 208 subjects (placebo = 95; Furocyst<sup>®</sup> = 113; age:18-45 years, BMI < 42 kg/m<sup>2</sup>) completed the investigation. The comparative efficacy of placebo and Furocyst<sup>®</sup> was assessed on the number of cysts, ovarian volume, hirsutism, LH:FSH ratio, titer of TSH, SHBG, prolactin and free testosterone. Key clinical parameters such as fasting blood glucose levels, HOMA Index, cholesterol, LDL, and triglyceride levels, as well as total blood chemistry were also investigated.</p><p><strong>Results: </strong>Furocyst<sup>®</sup> supplementation significantly reduced the number of cysts, ovarian volume, and hirsutism levels, as well as normalized the menstrual cycle in Furocyst<sup>®</sup>-treated subjects as compared to placebo group. Furocyst<sup>®</sup> significantly reduced luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels, and thyroid stimulating hormone (TSH) levels, and reduced the prolactin and SHBG levels. Furocyst<sup>®</sup> significantly reduced the fasting blood glucose levels, HOMA Index, cholesterol, LDL, and triglyceride levels as compared to the placebo group, while the free testosterone levels were significantly decreased in the Furocyst<sup>®</sup> group.</p><p><strong>Conclusion: </strong>The studies collectively demonstrated the efficacy of Furocyst<sup>®</sup> as a safe, natural phytochemical-based formulation to alleviate the symptoms of PCOS. No significant adverse events were observed.</p>","PeriodicalId":29768,"journal":{"name":"Journal of the American Nutrition Association","volume":"42 7","pages":"651-659"},"PeriodicalIF":6.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Nutrition Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/27697061.2022.2126410","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenemia, a quite common heterogenous endocrine/hormonal disorder, and accompanied by elevated androgen level, menstrual irregularity, and hirsutism. The consequences include infertility or miscarriage. It is a challenging problem to the physicians. In a one-arm, non-randomized preliminary investigation in fifty premenopausal women, we demonstrated the efficacy of Furocyst®, a patented, standardized Trigonella foenum-graecum extract, in ameliorating the symptoms of PCOS over a period of 90 consecutive days.

Objective: In the present study, a double-blind, two-arm, single-center, randomized, comparative study was conducted to assess the efficacy of Furocyst® (2 capsules of 500 mg/day) in 208 pre-menopausal women diagnosed with PCOS.

Methods: Ethical committee approval was obtained. A total of 208 subjects (placebo = 95; Furocyst® = 113; age:18-45 years, BMI < 42 kg/m2) completed the investigation. The comparative efficacy of placebo and Furocyst® was assessed on the number of cysts, ovarian volume, hirsutism, LH:FSH ratio, titer of TSH, SHBG, prolactin and free testosterone. Key clinical parameters such as fasting blood glucose levels, HOMA Index, cholesterol, LDL, and triglyceride levels, as well as total blood chemistry were also investigated.

Results: Furocyst® supplementation significantly reduced the number of cysts, ovarian volume, and hirsutism levels, as well as normalized the menstrual cycle in Furocyst®-treated subjects as compared to placebo group. Furocyst® significantly reduced luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels, and thyroid stimulating hormone (TSH) levels, and reduced the prolactin and SHBG levels. Furocyst® significantly reduced the fasting blood glucose levels, HOMA Index, cholesterol, LDL, and triglyceride levels as compared to the placebo group, while the free testosterone levels were significantly decreased in the Furocyst® group.

Conclusion: The studies collectively demonstrated the efficacy of Furocyst® as a safe, natural phytochemical-based formulation to alleviate the symptoms of PCOS. No significant adverse events were observed.

胡芦巴籽提取物(Trigonella foenum-graecum, furo囊肿®)对多囊卵巢综合征(PCOS)女性的疗效:一项随机、双盲、安慰剂对照研究。
简介:多囊卵巢综合征(PCOS)以高雄激素血症为特征,是一种相当常见的异质性内分泌/激素紊乱,并伴有雄激素水平升高、月经不规则和多毛。其后果包括不孕或流产。这对医生来说是一个具有挑战性的问题。在一项针对50名绝经前妇女的单臂非随机初步研究中,我们证明了furro囊肿®(一种标准化的专利葫芦丝提取物)在连续90天内改善PCOS症状的疗效。目的:本研究采用双盲、双组、单中心、随机对照研究,评估furo囊肿®(2粒胶囊,500 mg/天)对208例绝经前诊断为PCOS的妇女的疗效。方法:获得伦理委员会批准。共208名受试者(安慰剂= 95;furro囊肿®= 113;年龄:18-45岁,BMI < 42 kg/m2)完成调查。通过囊肿数量、卵巢体积、多毛、LH:FSH比值、TSH滴度、SHBG、催乳素和游离睾酮来评估安慰剂和furo囊肿®的比较疗效。关键临床参数如空腹血糖水平、HOMA指数、胆固醇、低密度脂蛋白和甘油三酯水平以及总血液化学也进行了调查。结果:与安慰剂组相比,补充furro囊肿显著减少囊肿数量、卵巢体积和多毛水平,并使经furro囊肿治疗的受试者月经周期正常化。毛囊®显著降低黄体生成素(LH)和促卵泡激素(FSH)水平,促甲状腺激素(TSH)水平,降低催乳素和SHBG水平。与安慰剂组相比,furro囊肿®显著降低了空腹血糖水平、HOMA指数、胆固醇、低密度脂蛋白和甘油三酯水平,而furro囊肿®组的游离睾酮水平显著降低。结论:这些研究共同证明了furro囊肿®作为一种安全、天然的基于植物化学物质的制剂,可以缓解多囊卵巢综合征的症状。未观察到明显的不良事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信